Bustin’ a move when the moment’s right.

that’s living VYVIDLY™

What does it mean to live VYVIDLY with CIDP? Find out more about this FDA-approved treatment below.

STAY UP TO DATE

CIDP=chronic inflammatory demyelinating polyneuropathy

Call 1-844-674-3504 for more information on the CIDP Ambassador Program

A different approach to CIDP

VYVGART Hytrulo works differently than other chronic inflammatory demyelinating polyneuropathy (CIDP) treatments, including IVIg, SCIg, PLEX, and steroids.

speaker

The first major innovation in CIDP treatment in over 30 years.*

droplet crossed out

The first and only plasma-free treatment approved by the FDA for CIDP.

flying clock

A first for CIDP—one weekly injection, given under the skin by a healthcare professional, that takes ~30 to 90 seconds.†

*VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.
†After administering your injection, your healthcare provider will monitor you for allergic reactions for at least 30 minutes.
FcRn=neonatal Fc receptor; IVIg=intravenous immunoglobulin; PLEX=plasma exchange; SCIg=subcutaneous immunoglobulin

About the VYVGART Hytrulo clinical study

document with magnifying glass

Learn about the effectiveness and safety of VYVGART Hytrulo—established in the largest clinical study in CIDP history

reduced risk

See how the VYVGART Hytrulo study measured the reduced risk of arm and leg symptoms getting worse

99%

of eligible patients chose to be part of an extended safety study and receive VYVGART Hytrulo (226 out of 228 patients)

Missed Breaking Through Today? Watch the milestone event here.

CIDP news this big deserved a virtual event. On Tuesday, October 1, 2024, the CIDP community gathered virtually for Breaking Through Today.

WATCH NOW
discussion guide image discussion guide image discussion guide image

Share your CIDP experience with your neurologist

The CIDP Doctor Discussion Guide is an easy-to-use tool that can help you track your CIDP symptoms and abilities. Providing a better understanding of your daily life with CIDP may help your doctor determine if VYVGART Hytrulo is right for you.

DOWNLOAD THE
DISCUSSION GUIDE
Icon_Patient_Caregiver_Heart@2x

Share your story

Your story is special because it is yours to tell. Sign up for the CIDP Patient Ambassador Program so you can make your mark on the CIDP community by sharing your personal experience living with or caring for someone with CIDP.

Make a difference and join us to inspire others. Learn more about the Patient Ambassador Program by calling us at 1-844-674-3504 or email amalia@mypatientstory.com.

My PRODUCT Y Path

Personalized support for every step of your VYVGART Hytrulo journey

After your doctor has prescribed you VYVGART Hytrulo, you can enroll in My VYVGART Path. Once enrolled, a Nurse Case Manager can assist you with tracking your symptoms and abilities to help prepare you for conversations with your doctor.

LEARN MORE
Live VYVIDLY Logo
Live VYVIDLY Logo

Have questions? Call 1-833-VYV-CIDP (1-833-898-2437) to speak with an educator about CIDP, how VYVGART Hytrulo works, study data, cost and coverage, and more.

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART HYTRULO may cause serious side effects, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
  • Allergic Reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
  • Infusion-Related Reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART HYTRULO, tell your doctor if you:

  • take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
  • have received or are scheduled to receive a vaccine (immunization), or
  • have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor.

Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART HYTRULO may cause serious side effects, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
  • Allergic Reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
  • Infusion-Related Reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART HYTRULO, tell your doctor if you:

  • take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
  • have received or are scheduled to receive a vaccine (immunization), or
  • have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor.

Questions? Call 1-833-VYV-CIDP
(1-833-898-2437)

This site is intended for patients and caregivers.

Disclaimer | Privacy Policy | Contact Us | Prescribing Information

VYVGART is a registered trademark of argenx.

VYVGART Hytrulo is a trademark of argenx.

LIVE VYVIDLY is a trademark of argenx.

LIVING VYVIDLY is a trademark of argenx.

For U.S. audiences only.

©2024 argenx 

US-VYV_HYT-24-00518 V1 12/2024

argenx logo